SHENZHEN-WOODY-VAPES
31.5.2022 18:00:06 CEST | Business Wire | Press release
ICCPP launched the full-range ceramic coil solution including disposable ceramic coil at Vaper Expo UK in Birmingham on May 27, 2022 -- a new category empowered by its "Digital Transformation" strategy, marking a new era in the global vape industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220528005017/en/
For the first time, ICCPP exhibited as a group and showcased its branded ODM+ solution and full-range ceramic coil solution. Adopting the Gene Tree technology, ICCPP’s ceramic coil will be integrated with the ODM+ business to promote a greater evolution in the industry. The ceramic coil, ICCPP’s first product released since it jointly launched the digital strategy with SAP and PwC, is bound to become a benchmark in the global vape industry.
Breakthrough: ceramic coil solution for disposable and multiple categories
In the vape industry, the ceramic coil technology is a key indicator of technological advancement of a company. ICCPP began to engage in the ceramic coil technology in 2019 by forming a R&D team led by "Peacock Program" talents, aiming to achieve an industry-leading level with the third or fourth generation of ceramic coil, and fully surpass the peers with the fifth or sixth generation.
Committed to becoming the leader in atomization technology, ICCPP brings a natural and pleasant vaping experience to the customers with its nanocrystalline (NC) materials and technical innovation. From thick film to thin film, from wire heating and surface heating to solid heating, ICCPP’s NC ceramic atomization technology has been constantly optimized the data model of the coil and enhancing the team's R&D strength to address the pain points in the vape coil industry. The newly launched Gene Tree thin film technology features five technical advantages, namely powder-free, improved safety, finer atomization, a longer lifespan, and an improved flavor.
As a result of the continuous endeavor of the R&D team, ICCPP recently launched the new generation of Gene Tree film technology and product applications, which, compared to the third-generation ceramic coil, has improved the flavor, increased the coil lifespan, and improved product reliability, bringing users a natural and pleasant vaping experience.
ICCPP will soon launch a disposable product equipped with the Gene Tree ceramic technology, with such features as longer-lasting flavor, more puffs, better restoration of flavor, and higher reliability, will bring revolutionary user experience, trigger a revolution in the industry, and become an industry milestone.
"Digital + technological innovation " to provide ODM + digital solution
ICCPP’s core advantages at the technical level are derived from its huge investment in scientific and technological innovation. On May 26, ICCPP announced the official launch of the "Digital Transformation Project" at its Shenzhen headquarters, becoming the world's first major company in the vape industry to cooperate with SAP and PwC. This marks that ICCPP will lead the industry into the phase of digital transformation.
The digital strategy refers to the overall digital innovation of the company integrating R&D, manufacturing, export, overseas marketing, etc. In the future, ICCPP will create an unprecedented "digital closed loop" and new digital competitiveness by creating digital R&D, digital manufacturing, digital marketing, and digital consumer experience. The mode of “digital + technological innovation” will become ICCPP’s underlying competitive advantage, including digitization + chips, digitization + fragrance, and digitization + smart manufacturing. "The company will drive development through digitalization and create new value through digitalization." Through digital transformation, the company aims to bring greater contributions to the industry and global consumers.
In order to develop ceramic coil, ICCPP quickly simulated the atomization effect by setting a data model and inputting parameters such as interface and size, so as to find the optimal configuration without sample production, thus accelerating product development and delivery. At present, ICCPP has a set of long-term plans for refillable and disposable ceramic coil products, and has reached cooperation intentions with at least 5 overseas major customers.
Mission of a leading going-out company: to empower global customers with technical innovation
ICCPP knows that customers in this era don’t need the traditional ODM anymore, but the branded ODM+. Therefore, the company has launched the new strategic partnership integrating brand positioning, user insight, product design, product development and after-sales, to guide customers to embrace new era of product customization.
Firstly, ICCPP promises to provide customers with the latest technology applications, and give them the same or even better technology as ICCPP’s own brands. Secondly, ICCPP shares all cutting-edge technologies with the entire industry chain in the strategic cooperation, including labs and institutes, automated factories, overseas user insights and global marketing services. This confidence of ICCPP comes from its rich and successful overseas experience and the ability to provide customers with one-stop services. ICCPP is committed to building two global platforms to empower customers: a truly open, Android-like vape technology platform, and a globalization platform based on years of overseas experience.
As the first strategic category after the digital upgrade, the ceramic coil solution can adapt to the full range of product lines. Emboding the industry's most advanced technologies, it is set to create a new vape category, improve user experience and bring changes to the market structure. On the one hand, ICCPP ODM+ business will undergo the digital upgrade and efficiency upgrade of the whole operation system integrating market survey, R&D, product design, order, delivery, and after-sales; on the other hand, it will establish in-depth cooperation with global customers on the ceramic coil solution. So far, ICCPP has reached cooperation intentions on this ceramic coil technology with many overseas major customers. ICCPP expects to bring more surprises to global customers and restructure the market in future.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220528005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
